Rezolute's Stock Plummets 90% After Failed Phase 3 Trial of Hypoglycemia Drug

Rezolute Faces Backlash Following Failed Phase 3 Trial of Hypoglycemia Drug

Rezolute, Inc. recently experiences a seismic shift in its trajectory following the failure of its Phase 3 sunRIZE trial for the hypoglycemia treatment ersodetug (erso). The company, which had previously expressed strong confidence in the drug’s efficacy and market potential, sees its stock plummet by as much as 90% during intraday trading on December 11, 2025. This trial was positioned as a critical juncture for Rezolute, as it aimed to demonstrate erso’s ability to improve the quality of life for patients suffering from hyperinsulinism. However, the trial results reveal a stark contrast to expectations, as the drug fails to meet both its primary and secondary endpoints, showing no statistically significant reduction in hypoglycemia events when compared to placebo.

In the lead-up to the trial, Rezolute had characterized the market opportunity as "incredible" and assured investors of a favorable outcome. The stark turnaround from hopeful assertions to disappointing results raises questions about the company’s communication strategy and its ability to manage investor expectations. The failure of ersodetug not only undermines investor confidence but also casts doubt on Rezolute's future prospects in the competitive biopharmaceutical landscape. Analysts swiftly respond to the news, downgrading the company's stock rating from outperform to neutral and slashing the price target from $12 to a mere $1, reflecting the drastic reassessment of the company's potential.

In light of the failed trial, a national shareholders' rights firm, Hagens Berman, initiates an investigation into whether Rezolute misled investors about erso's efficacy and commercial viability. The firm invites affected investors to come forward and share their experiences, suggesting that there may be grounds for claims regarding potential misinformation. Reed Kathrein, a partner at Hagens Berman, emphasizes the importance of transparency in communication, particularly when it comes to the effectiveness of drugs that have significant implications for patient care. As Rezolute navigates this tumultuous period, the company's future hinges on addressing these serious investor concerns and reassessing its strategic direction.

The fallout from the trial results not only impacts Rezolute’s stock but also highlights the broader challenges within the biopharmaceutical sector, where the stakes are high and the margin for error is slim. The incident serves as a cautionary tale for companies in the industry about the critical importance of maintaining clear and accurate communication with stakeholders, particularly when it involves the health and well-being of patients. As Rezolute works to recover from this setback, the industry watches closely, aware that the path forward will require not just scientific innovation but also a renewed commitment to transparency and accountability.